Number of Patients With 852A Response Using Modified Response Evaluation Criteria in Solid Tumors Up to Week 12 [clinicaltrials_resource:b8492c6158cfa440fb7de0e061a80bf3]
Stable disease in Non-Hogkin's Lymphoma = disease that does not satisfy complete (complete regression), partial (> or = 50% reduction) or progressive disease (increase of 25%) by at least a 4-week period. Since Acute Myelogenous Leukemia is not a solid tumor, Complete Response (CR) = <5% blasts with hematopoietic recovery (absolute neutrophil count >500) at 4 weeks.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Number of Patients With 852A Response Using Modified Response Evaluation Criteria in Solid Tumors Up to Week 12 [clinicaltrials_resource:b8492c6158cfa440fb7de0e061a80bf3]
Stable disease in Non-Hogkin's Lymphoma = disease that does not satisfy complete (complete regression), partial (> or = 50% reduction) or progressive disease (increase of 25%) by at least a 4-week period. Since Acute Myelogenous Leukemia is not a solid tumor, Complete Response (CR) = <5% blasts with hematopoietic recovery (absolute neutrophil count >500) at 4 weeks.
Bio2RDF identifier
b8492c6158cfa440fb7de0e061a80bf3
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:b8492c6158cfa440fb7de0e061a80bf3
measure [clinicaltrials_vocabulary:measure]
Number of Patients With 852A R ...... ation Criteria in Solid Tumors
time frame [clinicaltrials_vocabulary:time-frame]
Up to Week 12
description
Stable disease in Non-Hogkin's ...... rophil count >500) at 4 weeks.
identifier
clinicaltrials_resource:b8492c6158cfa440fb7de0e061a80bf3
title
Number of Patients With 852A R ...... in Solid Tumors Up to Week 12
@en
type
label
Number of Patients With 852A R ...... 92c6158cfa440fb7de0e061a80bf3]
@en